About

Leadership

The Boulder Peptide Foundation is led by a volunteer team of experts dedicated to advancing peptide science and fostering community collaboration.

The Boulder Peptide Foundation is governed by a Board of Directors with overall responsibility for advancing the Foundation’s mission.

The Scientific Advisory Board consists of key opinion leaders and preeminent experts drawn from both academic and industry backgrounds with expertise in peptide and protein therapeutics. The Scientific Advisory Board has the primary responsibility for organizing the scientific program for the Boulder Peptide Symposium.

All members of the leadership team serve in a purely voluntary capacity and follow our Conflict-of Interest policy.

2025-2026 Scientific Advisory Board

Directors

The Boulder Peptide Foundation is guided by a volunteer Board of Directors, comprised of leaders from academia and industry committed to advancing peptide research and innovation.

YVONNE ANGELL, PH.D.

President and Member Board of Directors
Dr. Yvonne Angell has more than twenty years experience in the field of peptide therapeutics. She has initiated, led and advanced research teams and programs at Eli Lilly, Pfizer, Affymax, Ipsen, ChemPartner, GenEdit, and is currently Executive Director of TIDES Discovery Project Management at STA Pharmaceuticals, a WuXi Apptec company. Her primary expertise lies in design, synthesis, lead optimization and early development of therapeutic peptides, oligonucleotides, proteins and conjugates. In addition, she has designed and optimized novel polymers to enable non-viral, non-lipid nanoparticle delivery for tissue targeting of genetic therapies. She has experience in a wide range of therapeutic areas including hematology, oncology, neurology and endocrinology. She has advanced many drug discovery programs including ten drug candidates into preclinical development, one to the market and one in phase 2 clinical trials.
She is active in her field and currently serves as President of the Boulder Peptide Foundation and founder of TIDEtalks. She also plays an active role on the advisory boards for several prominent conferences in the peptide and oligo therapeutic fields. She received her PhD from the University of Wisconsin, Madison, and carried out postdoctoral research as an NIH fellow at the University of Minnesota, Minneapolis. She is an inventor on many patents and has numerous scientific publications.

REBECCA NOFSINGER, PH.D.

Vice President, Chair Scientific Advisory Board and Member Board of Directors
Dr. Rebecca Nofsinger was previously the Drug Delivery Session Chair for BPS. She is currently a Senior Director of ADME within Eli Lilly and Company. Dr Nofsinger has had over 15 years expertise in both peptide and small molecule drug development. Dr. Nofsinger’ s work activities relate to late-stage drug development and nonclinical strategy for regulatory filings as well as evaluating ADME challenges on drug discovery teams. Dr. Nofsinger has also worked in the Pharmaceutical Science organization within Merck & Co., Inc where she was involved in oral biopharmaceutics focusing on supporting oral formulation development across various clinical development stages with an expertise in oral peptide permeation, discovery/development interface, and prodrug development. She has presented at numerous conferences and authored/co-authored over 15 peer reviewed research and review articles.
Dr. Rebecca Nofsinger was previously the Drug Delivery Session Chair for BPS. She is currently a Senior Director of ADME within Eli Lilly and Company. Dr Nofsinger has had over 15 years expertise in both peptide and small molecule drug development. Dr. Nofsinger’ s work activities relate to late-stage drug development and nonclinical strategy for regulatory filings as well as evaluating ADME challenges on drug discovery teams. Dr. Nofsinger has also worked in the Pharmaceutical Science organization within Merck & Co., Inc where she was involved in oral biopharmaceutics focusing on supporting oral formulation development across various clinical development stages with an expertise in oral peptide permeation, discovery/development interface, and prodrug development. She has presented at numerous conferences and authored/co-authored over 15 peer reviewed research and review articles.

SYED REZA, PH.D., M.D.

Secretary, Member Board of Directors
Syed Reza is a physician scientist with over fifteen years technology commercialization experience in pharmaceutical sciences. Syed has worked on diverse formulation development projects involving peptides, siRNA, proteins and small molecules. Syed is currently the Director of Business Development for NOF Corporation specializing in gene therapy applications of lipid nanoparticles. Previously Syed was Head of US Business Development for Octoplus N.V. and responsible for tech transfer and licensing of the protein microsphere technology portfolio. From 2008 to 2011 he was the Business Development Manager for Hoffmann-LaRoche in Boulder Colorado responsible for developing the contract peptide manufacturing business. Syed has also chaired the Annual Roche Colorado Peptide Symposium since 2009. Syed obtained his MD-PhD from University of Medicine of New Jersey in 2003 and his B.S in Chemistry from The George Washington University in 1993.

KEVIN MCCOWEN

KEVIN MCCOWEN

Treasurer, Member Board of Directors

Kevin McCowen is the Founder of McCowen Analytical Contract Labs (MAC-Labs) in San Diego. Kevin began his career in bioanalytical chemistry at Amylin Pharmaceuticals in the early 2000s, working as a mass spectrometrist focused on discovering novel therapeutic peptides. During his tenure, he contributed to the development and commercialization of Symlin and Byetta. After nearly a decade at Amylin, he held R&D positions at ARUP Laboratories in Utah and Prometheus Laboratories in San Diego, where he developed diagnostic tests for newborn screening and the commercially available ANSER Dx. Subsequently, Kevin served as Supervisor of Analytical Development at Aji Bio-Pharma Services for five years. He then transitioned to roles in marketing and sales, including Manager of Vertical Marketing at Thermo Scientific and Regional Sales Manager for the Western U.S. and Canada at Wyatt Technology. In 2022, he founded MAC-Labs, a contract analytical chemistry provider in San Diego. Throughout his career, Kevin has contributed to multiple publications in peer reviewed scientific journals. Kevin holds a Master of Science degree in Biomedical Science from the University of Utah, where he investigated peptide exchange reactions with major histocompatibility complex class II molecules.

Kevin McCowen is the Founder of McCowen Analytical Contract Labs (MAC-Labs) in San Diego. Kevin began his career in bioanalytical chemistry at Amylin Pharmaceuticals in the early 2000s, working as a mass spectrometrist focused on discovering novel therapeutic peptides. During his tenure, he contributed to the development and commercialization of Symlin and Byetta. After nearly a decade at Amylin, he held R&D positions at ARUP Laboratories in Utah and Prometheus Laboratories in San Diego, where he developed diagnostic tests for newborn screening and the commercially available ANSER Dx. Subsequently, Kevin served as Supervisor of Analytical Development at Aji Bio-Pharma Services for five years. He then transitioned to roles in marketing and sales, including Manager of Vertical Marketing at Thermo Scientific and Regional Sales Manager for the Western U.S. and Canada at Wyatt Technology. In 2022, he founded MAC-Labs, a contract analytical chemistry provider in San Diego. Throughout his career, Kevin has contributed to multiple publications in peer reviewed scientific journals. Kevin holds a Master of Science degree in Biomedical Science from the University of Utah, where he investigated peptide exchange reactions with major histocompatibility complex class II molecules.

Betsy Powell

Co-Manager of the Boulder Peptide Foundation

Betsy Powell is a conference management professional based in San Diego, California. She earned her bachelor’s degree from San Diego State University and her MBA from Ball State University with an emphasis in Healthcare Administration, building a strong foundation in strategic planning, business development, and marketing.

Lauren Cline, Ph.D

Lauren Cline, Ph.D

Co-Manager of the Boulder Peptide Foundation

Lauren Cline has extensive experience managing non-profit professional organizations in the field of peptide science. Her passion for peptides began as an undergraduate researcher in Dr. Joel Schneider’s lab at the University of Delaware, where she earned her B.S. in Biochemistry in 2004. She went on to complete her Ph.D. in Biological Chemistry at the University of North Carolina at Chapel Hill in 2009 under the mentorship of Dr. Marcey Waters, focusing on the design of peptides that bind RNA. Following her doctoral work, Lauren conducted postdoctoral research in Dr. Steve Regen’s lab at Lehigh University, studying membrane-active compounds. In 2017, she became the Association Manager for the American Peptide Society, where she supports the global peptide community through strategic leadership and organizational management. In 2022, she also joined the Boulder Peptide Foundation team, furthering her commitment to advancing peptide research and collaboration. Be sure to say hello to Lauren at the next peptide conference—you’ll likely find her helping to make it all run smoothly!

Lauren Cline has extensive experience managing non-profit professional organizations in the field of peptide science. Her passion for peptides began as an undergraduate researcher in Dr. Joel Schneider’s lab at the University of Delaware, where she earned her B.S. in Biochemistry in 2004. She went on to complete her Ph.D. in Biological Chemistry at the University of North Carolina at Chapel Hill in 2009 under the mentorship of Dr. Marcey Waters, focusing on the design of peptides that bind RNA. Following her doctoral work, Lauren conducted postdoctoral research in Dr. Steve Regen’s lab at Lehigh University, studying membrane-active compounds. In 2017, she became the Association Manager for the American Peptide Society, where she supports the global peptide community through strategic leadership and organizational management. In 2022, she also joined the Boulder Peptide Foundation team, furthering her commitment to advancing peptide research and collaboration. Be sure to say hello to Lauren at the next peptide conference—you’ll likely find her helping to make it all run smoothly!

Information for BPS Presenters

The Boulder Peptide Foundation was established to further the science and knowledge of peptide technology to develop novel therapeutics, biomaterials, medical diagnostics and other beneficial uses for mankind. As part of this goal we run several programs to support career advancement, seminars and educational events. Join us on our mission to expand the applications of peptide science.

Information for BPS Presenters

The purpose of the Boulder Peptide Symposium is to encourage sharing of information related to peptide therapeutic development with an emphasis on the technical, scientific and regulatory aspects of the pharmaceutical development. Presentations that demonstrate original thinking or share experiences from case studies in product development shall receive priority over others.

The Boulder Peptide Symposium offers multiple opportunities for participants to present.

Oral Presentations in Scientific Sessions

The session topics for Scientific Program are Peptides in the Clinic, Drug Delivery, Chemistry of Complex Peptides, Spotlight on Discovery, and Peptide Showcase. Abstracts may be submitted via the Apply to Present page on the website. Submissions will be reviewed by the Scientific Advisory Board on a monthly basis and the speaker will be notified of a decision.

Presentation length: Format is 25-30 minutes slide presentation with 5-10 minutes for Q&A, with the exception of Peptide Showcase talks which are 10 minute slide presentations with 5 minutes for Q&A. Please confirm with your session chair to confirm the exact presentation length.

Invited Speakers: Speakers are requested to supply their presentation details 30 days after receiving an invitation to present.

Program Book Deadline: Final abstract and title must be provided no later than September 1st. No changes to the program are possible after this date.

Presentation Format: Oral presenters please provide your presentation slides to the A/V table on the day of your presentation.

Lodging: All speakers are requested to reserve their own room. Discount rates at the conference hotel are available until August 16th.

Registration: All speakers, excluding sponsored presentation speakers, receive a complimentary registration upon approval of the abstract.

Peptide Showcase Description

The Peptide Showcase is an opportunity for an individual or company to “showcase” new ideas, technology and pipeline assets. Priority shall be given to presentations from biotech and startup companies. Service providers and vendors are not eligible. Speakers in the session receive a complimentary event registration.

Posters

Posters can be presented on any topic relevant to peptides including original research, innovative products and technologies.

Eligibility- Any attendee (from academia, industry, biotech or vendor/sponsor) can present a poster. The presentation must contain original scientific thinking. To submit a poster go to the Submit a Poster link from the meeting menu. All submissions are reviewed on a rolling basis and will be notified of approval. September 1st is the last day to submit a poster abstract. Approved posters are published on the BPF website.

A 30 ” x 40″ board shall be provided with thumb tacks. Board will be on an easel and can be rotated for either landscape or portrait formats. Once you apply for a poster, you will get email confirmation that your poster was accepted. The poster session and number assignments will be emailed one week before the Symposium.

Poster boards shall be available for display from 8am to 8pm the day of your assigned poster session. See the program agenda for the poster session schedule.

Public Release

Every presentation at the Boulder Peptide Symposium is automatically recorded. Speakers are required to give consent for sharing of the presentation video with the peptide community.